NEETHU ATHIMATTATHIL: Open Payments
NPI 1922744218 · DOUGLASVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,113 in 46 payments from 15 companies in 2025. Trend: 2023 $2,244 · 2024 $1,680 · 2025 $1,113
Food & beverage: $1,113
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $189 |
| GlaxoSmithKline, LLC. | 10 | $154 |
| Novartis Pharmaceuticals Corporation | 5 | $136 |
| GENZYME CORPORATION | 4 | $108 |
| CSL Behring | 3 | $107 |
| Grifols USA, LLC | 2 | $61 |
| Lilly USA, LLC | 2 | $54 |
| BioCryst US Sales Co., LLC | 2 | $54 |
| Amgen Inc. | 2 | $53 |
| Organon LLC | 2 | $45 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, XOLAIR, FASENRA, Hizentra, Xembify, EBGLYSS.
Industry payments across GA — which companies pay providers there.
